To carry out their activities, Research Teams of the Frédéric Joliot Institute for Life Sciences have developed high-profile technological platforms in many areas : biomedical imaging, structural biology, metabolomics, High-Throughput screening, level 3 microbiological safety laboratory...
Within the Institute, the "Funding Research and Technology Transfer" team is at your disposal to identify the scientists and the skills you need to set up a joint project, to define the terms of a collaboration contract or study.
Whether you are an academic, a SME or an industrialist, our team informs and advices you about the possibilities of consortium assembly, technology transfer, patent licensing or use of our platforms.
The team is also at the disposal of the researchers of the institute to accompany them in achieving their valorization objectives.
Researchers at BioMaps (SHFJ) have succeeded in determining the interaction dynamics of buprenorphine, an opioid drug with a particularly complex pharmacology, with its brain receptors in vivo. To do so, they developed an original PET imaging approach based on the use of the radiolabeled molecule (11C-buprenorphine).
Researchers at the CEA-Joliot Institute (Carbon-14 labeling Laboratory), in collaboration with teams from AstraZeneca, Sanofi and Nimbe (CEA-Iramis), have developed a labeling method, based on nitrile exchange using nickel catalysis. This method is currently under study at Sanofi for the labeling of a drug candidate.
The Ginkgo team (BAOBAB / NeuroSpin), in collaboration with the Inserm iBRAIN U1253 unit (Tours), published in NeuroImage the first anatomical atlas of the human brainstem with at mesoscopic scaleresolution from extreme ultra-high field MRI. Freely available as a wiki, this atlas will be used in particular by neuroanatomists and neurosurgeons.
Research from CEA, Collège de France, CNRS and Université Paris 8 shows that humans share a universal ability to understand abstract geometric concepts. This human ability does not depend on age, culture or education, but does not exist in the non-human primates tested. PNAS has just published their results.
Researchers from NeuroSpin and CNRGH (Jacob Institute) have studied, on a genome-wide scale, the potential associations of haplotypes (set of variants located side by side on a chromosome) with the opening value of imaged brain sulci, indicator of brain aging, from the UK Biobank neuroimaging-genetics cohort.
An international consortium of scientists, including an I2BC team, has just deciphered the functioning of FAP (Fatty Acid Photodecarboxylase), a key photoenzyme for the production of biofuels and other high value added molecules. This work, published in Science, was the object of a CEA press release.
Teams from IPMC and SIMoS (DMTS) defined the molecular determinants of the interaction between Mambalgin-1, an analgesic peptide isolated from black mamba venom, and its target, ASIC1 (Acid-Sensing Ion Channels), to model, using molecular dynamics, this complex. The resulting model provides clues to develop blockers of ASIC1, interesting targets for clinical pain relief applications.
The European Commission once more places its trust on Multiwave company and its partners, Aix-Marseille Université , CEA and Université Catholique de Louvain to revolutionize ultra-high field magnetic resonance imaging of the brain.
Rebeccah SLATER (University of Oxford, St John's College Professorial Fellow, Department of Paediatrics) will give a talk on Zoom.
CEA is a French government-funded technological research organisation in four main areas: low-carbon energies, defense and security, information technologies and health technologies. A prominent player in the European Research Area, it is involved in setting up collaborative projects with many partners around the world.